Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 6/20 | 0.58 |
| ▸ | CTSK | P43235 | 5/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479141 | 1.00 | ACE (0.61) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL479202 | 0.88 | ACE (0.48) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL479204 | 0.88 | ACE (0.48) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL478955 | 0.88 | ACE (0.50) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL3040553 | 0.88 | ACE (0.64) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL478503 | 0.87 | ACE (0.47) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL478502 | 0.87 | ACE (0.47) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL3416318 | 0.85 | L3MBTL1 (0.47) | ACEATM | |
| SCHEMBL1197426 | 0.83 | ACE (0.61) | ACECTSSCTSKCTSBCTSL | |
| SCHEMBL1791910 | 0.83 | ACE (0.56) | ACECTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3650464-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019007383-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | 凯惠科技发展(上海)有限公司 | 2019-01-10 | — | — | WO | disclosed |
| US-8604056-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-10 | — | — | US | disclosed |
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-25 | — | — | US | disclosed |
| US-8252830-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| EP-1981854-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7951834-B2 | Angiotensin I-converting enzyme (ACE) inhibitors | UNIVERSITY OF CAPE TOWN (ZA) | 2011-05-31 | — | — | US | disclosed |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-03 | — | — | US | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
| EP-2265601-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7842708-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7626039-B2 | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281160-A1 | Angiotensin I-converting enzyme (ace) inhibitors | ANGIODESIGN (UK) LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281160-A1 | Angiotensin I-converting enzyme (ace) inhibitors | ANGIODESIGN (UK) LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| WO-2009114677-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB CO. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270853-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | ACE 117/4885CTSS 514/4885CTSK 664/4885 |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | ACE 410/4885CTSS 541/4885CTSK 273/4885 |
| US-20080161373-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | ACE 117/4885CTSS 514/4885CTSK 664/4885 |
| US-20090281160-A1 | Angiotensin I-converting enzyme (ace) inhibitors | ACE, ACE2, REN | ACE 1/4885CTSS 172/4885CTSK 148/4885 |
| US-20200172575-A1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | KISS1R, VIP, NPY1R | ACE 1694/4885CTSS 2804/4885CTSK 1962/4885 |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | ACE 117/4885CTSS 514/4885CTSK 664/4885 |
| US-20110028446-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | ACE 117/4885CTSS 514/4885CTSK 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.